SARCULATOR
Predict disease risk and track patient progress
DIGITAL FOREST SRL
iPhone Screenshots
iPad Screenshots
Description
Provides survival predictions for patients with retroperitoneal sarcoma and soft tissue sarcoma. It estimates 5-year and 10-year overall survival rates and disease-free survival. Physicians can input patient data to receive predictive analytics.
This app is meant to be used only by physicians and it is not meant to make clinical decisions (the clinical usefulness of the two models has not been tested) but to be used as an informative tool to improve the predictive capability of a physician.
Two kinds of predictions are possible:
- RPS: 5-year overall survival (OS) and 5-year disease-free survival (DFS) in primary resected retroperitoneal sarcoma (RPS) patients. .
- STS: 5- and 10-year overall survival (OS) and cumulative incidence of distant metastasis (CCI of DM) in primary resected extremity STS patients.
App information from Apple App Store. SARCULATOR and related trademarks belong to DIGITAL FOREST SRL.